Specifications include, but are not limited to: The Department of Consumer and Business Services (Agency), intends to purchase database access for ICER Analytics: Evidence Compendium and Interactive Modeler for up to 10 concurrent users. This access includes on-going updates to the data. The ICER Analytics database is only available from Evidence for Healthcare Improvement, Institute for Clinical and Economic Review (ICER). ICER Analytics provides unique and proprietary data that is necessary to accurately assess fees, analyze costs, and research data related to drug pricing that would be contained in reports published by the Agency. Most notably, the data will be used to assist with Section 3 of SB844, as follows: “The Department of Consumer Business Services shall adopt by rule, in consultation with the Prescription Drug Affordability Board, annual fees to be paid by manufacturers that sell prescription drugs in this state. The fees shall be established in amounts necessary to meet the costs of the department and the board in administering sections 1 to 3 of this 2021 Act. The fees shall be imposed based on a manufacturer’s share of gross revenue from sales of prescription drugs in this state.” On October 17, 2022, Agency issued an agreement to evaluate the software using a 30 day free trial license. On November 8, 2022, Agency received approval from EIS to purchase access the database for up to three years or $30,000. Please note: This is a Sole Source Notification.
